Explore

Rapid Read Rapid Read
Cochrane Review Finds Limited Efficacy in Alzheimer's Amyloid Drugs

Cochrane Review Finds Limited Efficacy in Alzheimer's Amyloid Drugs

A Cochrane Collaboration review has concluded that amyloid beta-targeting drugs for Alzheimer's disease show limited clinical efficacy. The analysis, which included data from 17 clinical trials involving 20,342 participants, found that these drugs have minimal impact on cognitive decline and dementia severity, while increasing the risk of brain bleeding and swelling. The review specifically examined Eisai/Biogen's Leqembi and Eli Lilly's Kisunla, among others. Despite some statistically significant results in early trials, the review emphasizes the lack of meaningful clinical benefits for patients. The findings have sparked debate among researchers, with some advocating for exploring alternative treatment mechanisms.
Rapid Read Rapid Read
Cochrane Review Finds Amyloid-Targeting Alzheimer's Drugs Likely Ineffective for Mild Dementia

Cochrane Review Finds Amyloid-Targeting Alzheimer's Drugs Likely Ineffective for Mild Dementia

A recent Cochrane review has concluded that amyloid-beta-targeting monoclonal antibodies, specifically donanemab and lecanemab, are probably not effective in treating mild cognitive impairment or mild dementia associated with Alzheimer's disease (AD). The review analyzed 17 studies involving 20,342 participants, assessing outcomes over periods of 12, 18, 24, and more than 24 months. The findings suggest that these drugs result in little to no difference in functional ability as measured by the Alzheimer's Disease Cooperative Study - Activities of Daily Living scale. The review also noted a small increase in amyloid-related imaging abnormalities related to edema (ARIA E) at 18 months. However, the studies did not clearly differentiate between symptomatic and asymptomatic cases of brain swelling and microbleeds, leaving a gap in understanding the seriousness of potential side effects.
Trendline Trendline
FDA Demands Safety Data for Lilly's Oral GLP-1 Drug Foundayo

FDA Demands Safety Data for Lilly's Oral GLP-1 Drug Foundayo

FDA Demands Safety Data for Lilly's Oral GLP-1 Drug Foundayo
Trendline Trendline
Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval
Rapid Read Rapid Read
UK Health Minister Warns of Risks from Low Medicines Pricing on Supply Security

UK Health Minister Warns of Risks from Low Medicines Pricing on Supply Security

UK Health Minister Zubir Ahmed has expressed concerns about the potential risks to long-term supply security due to the low prices paid for medicines in the UK. Speaking at a parliamentary reception, Ahmed highlighted the challenge of maintaining supply resilience while achieving some of the lowest medicine prices internationally. The event, hosted by the All-Party Parliamentary Group on Pharmacy, emphasized the need for investment in medicines pricing to ensure reliable access to medicines. The trade association Medicines UK noted that the competitive market has led to significant savings for the NHS, but also warned that low prices could lead manufacturers to prioritize other markets.
Trendline Trendline
FDA Requests Additional Safety Data for Eli Lilly’s New Obesity Drug Foundayo

FDA Requests Additional Safety Data for Eli Lilly’s New Obesity Drug Foundayo

FDA Requests Additional Safety Data for Eli Lilly’s New Obesity Drug Foundayo
Trendline Trendline
FDA Demands Safety Data for Eli Lilly's Oral GLP-1 Drug Foundayo Amidst Market Competition

FDA Demands Safety Data for Eli Lilly's Oral GLP-1 Drug Foundayo Amidst Market Competition

FDA Demands Safety Data for Eli Lilly's Oral GLP-1 Drug Foundayo Amidst Market Competition
Trendline Trendline
Unapproved Weight-Loss Drug Retatrutide Gains Attention Despite FDA Status

Unapproved Weight-Loss Drug Retatrutide Gains Attention Despite FDA Status

Unapproved Weight-Loss Drug Retatrutide Gains Attention Despite FDA Status
Rapid Read Rapid Read
GLP-1 Drug Usage Patterns Reveal Challenges in Long-Term Adherence

GLP-1 Drug Usage Patterns Reveal Challenges in Long-Term Adherence

GLP-1 drugs, such as Ozempic and Zepbound, are increasingly used for diabetes and obesity treatment, yet many patients discontinue their use. Dr. Jaime Almandoz from the University of Texas Southwestern Medical Center found that less than 25% of patients remain on these medications after a year. Factors contributing to this include cost, insurance loss, and side effects. Despite this, a significant number of patients express intentions to restart the medication. The pharmaceutical industry is advocating for changes in Medicare rules to increase accessibility, while concerns about muscle loss from intermittent use are being raised by experts.
Trendline Trendline
GSK Gains Additional Marketing Approval for Depemokimab with Adimab Collaboration

GSK Gains Additional Marketing Approval for Depemokimab with Adimab Collaboration

GSK Gains Additional Marketing Approval for Depemokimab with Adimab Collaboration
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Rapid Read Rapid Read
New Research Challenges Alzheimer's Plaque Theory, Suggests Protein Competition

New Research Challenges Alzheimer's Plaque Theory, Suggests Protein Competition

A study from the University of California, Riverside, published in PNAS Nexus, challenges the traditional view that Alzheimer's disease is primarily caused by amyloid plaques. The research suggests that the disease may result from a competition between amyloid beta (a-beta) and tau proteins within neurons. The study found that a-beta and tau compete for binding sites on microtubules, essential structures for cellular transport. This competition could displace tau, disrupting cellular functions and potentially leading to Alzheimer's symptoms. The findings propose that the buildup of these proteins might be a consequence rather than the cause of the disease, offering a new perspective on Alzheimer's pathology.